Identification of Circulating MicroRNA Signatures in Crohn's Disease Using the Nanostring nCounter Technology

Current clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activi...

Full description

Saved in:
Bibliographic Details
Published inInflammatory bowel diseases Vol. 22; no. 9; pp. 2063 - 2069
Main Authors Oikonomopoulos, Angelos, Polytarchou, Christos, Joshi, Swapna, Hommes, Daniel W., Iliopoulos, Dimitrios
Format Journal Article
LanguageEnglish
Published Oxford, UK Oxford University Press 01.09.2016
Subjects
Online AccessGet full text
ISSN1078-0998
1536-4844
1536-4844
DOI10.1097/MIB.0000000000000883

Cover

Abstract Current clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients.MethodsTo test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey–Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey–Bradshaw index.ResultsWe identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement.ConclusionsCirculating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities.
AbstractList BackgroundCurrent clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients.MethodsTo test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey–Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey–Bradshaw index.ResultsWe identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement.ConclusionsCirculating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities.
Background: Current clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients. Methods: To test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey-Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey-Bradshaw index. Results: We identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement. Conclusions: Circulating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities.
Current clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients.BACKGROUNDCurrent clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients.To test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey-Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey-Bradshaw index.METHODSTo test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey-Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey-Bradshaw index.We identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement.RESULTSWe identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement.Circulating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities.CONCLUSIONSCirculating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities.
Current clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients. To test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey-Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey-Bradshaw index. We identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement. Circulating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities.
Current clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients.MethodsTo test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey–Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey–Bradshaw index.ResultsWe identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement.ConclusionsCirculating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities.
Author Hommes, Daniel W.
Iliopoulos, Dimitrios
Oikonomopoulos, Angelos
Joshi, Swapna
Polytarchou, Christos
Author_xml – sequence: 1
  givenname: Angelos
  surname: Oikonomopoulos
  fullname: Oikonomopoulos, Angelos
  organization: Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California
– sequence: 2
  givenname: Christos
  surname: Polytarchou
  fullname: Polytarchou, Christos
  organization: †College of Arts and Science, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom
– sequence: 3
  givenname: Swapna
  surname: Joshi
  fullname: Joshi, Swapna
  organization: ‡Center for Systems Biomedicine, Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California
– sequence: 4
  givenname: Daniel W.
  surname: Hommes
  fullname: Hommes, Daniel W.
  organization: Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California
– sequence: 5
  givenname: Dimitrios
  surname: Iliopoulos
  fullname: Iliopoulos, Dimitrios
  email: diliopoulos@mednet.ucla.edu
  organization: ‡Center for Systems Biomedicine, Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27542126$$D View this record in MEDLINE/PubMed
BookMark eNqNkctuFDEQRS0URB7wBwhZYgGbTvzsttmF5jVSEiRI1i3Hrp5x1GNPbPcif4-HCQjNhrgWdknnllX3HqODEAMg9JqSU0p0d3a5-HhK_j1K8WfoiEreNkIJcVDfpFMN0VodouOc7whhtfQLdMg6KRhl7RFaLxyE4kdvTfEx4Dji3ic7T7UNS3zpbYo_rs7xT78MpswJMvYB9ymuwruMP_kMJgO-yVu4rABfmRBzSds29HEOBRK-BrsKcYrLh5fo-WimDK8e7xN08-Xzdf-tufj-ddGfXzRWSFEaMEZxIYzstKNyFMZx4J3UsusEMMGts7dsVEwTyplyVPMOnFLOUTcqKQ0_Qe93czcp3s-Qy7D22cI0mQBxzgNVreKUay2fgFKmqrWirejbPfQuzinURQZOW60oYUJU6s0jNd-uwQ2b5NcmPQx_PK-A2AHV2pwTjH8RSoZttEONdtiPtso-7MmsL79DK8n46X_is504zpunffcLInSz1Q
CitedBy_id crossref_primary_10_1038_s41598_018_35876_5
crossref_primary_10_3389_fimmu_2022_865777
crossref_primary_10_1007_s00604_024_06405_1
crossref_primary_10_1038_s41598_019_45570_9
crossref_primary_10_1159_000511641
crossref_primary_10_1159_000515522
crossref_primary_10_18632_aging_202428
crossref_primary_10_3389_fphar_2022_813659
crossref_primary_10_1021_acsnano_7b04878
crossref_primary_10_18632_aging_101199
crossref_primary_10_1016_j_bbcan_2017_06_005
crossref_primary_10_1093_gastro_goab056
crossref_primary_10_1007_s40291_020_00447_w
crossref_primary_10_1038_cddis_2017_440
crossref_primary_10_1002_lom3_10594
crossref_primary_10_1093_ecco_jcc_jjz120
crossref_primary_10_1007_s40291_017_0298_4
crossref_primary_10_3390_ijms20153662
crossref_primary_10_1053_j_gastro_2021_03_050
crossref_primary_10_1021_acssensors_9b00752
crossref_primary_10_3389_fonc_2023_1288077
crossref_primary_10_3389_fendo_2022_888948
crossref_primary_10_1016_j_exger_2017_06_017
crossref_primary_10_2217_epi_2016_0155
Cites_doi 10.1016/S0140-6736(07)60750-8
10.1073/pnas.0804549105
10.1016/S0140-6736(12)60026-9
10.1097/MOG.0000000000000081
10.1038/nrgastro.2015.34
10.1053/j.gastro.2010.11.058
10.1136/gut.27.7.809
10.1097/01.MIB.0000173271.18319.53
10.1136/gut.30.9.1236
10.1016/j.cell.2011.10.043
10.1053/j.gastro.2013.07.001
10.1097/MIB.0000000000000547
10.1016/j.crohns.2014.02.012
10.1371/journal.pone.0031241
10.1200/JCO.2012.46.1558
10.1016/S0140-6736(12)60150-0
10.1016/j.crohns.2012.02.006
10.1371/journal.pone.0140155
10.1016/S0140-6736(80)92767-1
10.1097/MPG.0b013e31822200cc
10.1002/ibd.21695
10.1053/j.gastro.2008.07.068
10.1053/j.gastro.2015.05.057
10.1002/ibd.21450
10.1111/j.1349-7006.2010.01650.x
10.1111/cei.12104
10.1038/nrd3864
10.1016/j.trsl.2012.01.001
10.1080/00365520500320094
10.1097/MIB.0b013e3182810066
10.1038/ni.f.209
10.1111/j.1572-0241.2008.02158.x
10.1097/01.MIB.0000436954.70596.9b
10.1371/journal.pone.0013160
ContentType Journal Article
Copyright Copyright © 2016 Crohn's & Colitis Foundation of America, Inc. 2016
Copyright © 2016 Crohn's & Colitis Foundation of America, Inc.
Copyright_xml – notice: Copyright © 2016 Crohn's & Colitis Foundation of America, Inc. 2016
– notice: Copyright © 2016 Crohn's & Colitis Foundation of America, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
7T5
H94
DOI 10.1097/MIB.0000000000000883
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central - New (Subscription)
ProQuest One
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
Immunology Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
DatabaseTitleList ProQuest One Academic Middle East (New)
AIDS and Cancer Research Abstracts
MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1536-4844
EndPage 2069
ExternalDocumentID 27542126
10_1097_MIB_0000000000000883
10.1097/MIB.0000000000000883
Genre Journal Article
GroupedDBID ---
.Z2
0R~
1OC
3WU
48X
53G
5GY
5VS
5WD
66C
7O~
8-0
8UM
AAAXR
AABZA
AACZT
AAKAS
AAPQZ
AAPXW
AARHZ
AARTV
AAUAY
AAVAP
AAYEP
ABBUW
ABDFA
ABEJV
ABGNP
ABJNI
ABNHQ
ABOCM
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVJ
ABXVV
ABZAD
ACDDN
ACEWG
ACGFO
ACGFS
ACUTJ
ACWDW
ACWRI
ACXNZ
ACYHN
ADBBV
ADBIZ
ADGZP
ADIPN
ADQBN
ADRTK
ADVEK
ADZCM
AENEX
AETBJ
AFFZL
AFOFC
AFTRI
AFUWQ
AFXAL
AGINJ
AGQXC
AGUTN
AHMBA
AHMMS
AIJEX
AIZYK
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ATGXG
AWKKM
BAYMD
BCRHZ
BEYMZ
BOYCO
BTRTY
C45
CDBKE
CS3
DAKXR
DR2
DU5
E.X
E3Z
EBS
EJD
ENERS
EX3
F5P
FECEO
FL-
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H0~
HZ~
IN~
IX1
KBUDW
KOP
KSI
KSN
LAW
MHKGH
NNB
NOMLY
NOYVH
NVLIB
N~7
N~B
O9-
OAUYM
OCZFY
ODMLO
OIG
OJZSN
OPAEJ
OVD
OWPYF
P2P
PAFKI
PQQKQ
QRW
ROX
RUSNO
RX1
S4S
TEORI
V2E
WOW
XV2
YAYTL
YKOAZ
YXANX
ZFV
31~
4.4
7X7
8-1
88E
8F7
8FI
8FJ
AAJQQ
AAPGJ
AAUQX
AAWDT
AAYXX
ABUWG
ACFRR
ACVCV
ACXQS
ACZBC
ADMTO
ADNBA
AEMQT
AFBPY
AFFQV
AFKRA
AFYAG
AFZJQ
AGKRT
AGMDO
AGORE
AHGBF
AHRYX
AJAOE
AJBYB
AJDVS
AJNCP
AJNYG
ALXQX
APJGH
AQDSO
AQKUS
AVNTJ
BENPR
CCPQU
CITATION
EIHJH
FYUFA
H13
HMCUK
IAO
IHR
ITC
JXSIZ
LH4
LW6
M1P
MBLQV
NU-
OBFPC
OCUKA
ORVUJ
PHGZM
PHGZT
PSQYO
ROL
TMA
UKHRP
W99
WOQ
Y6R
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
PUEGO
7X8
7T5
H94
ID FETCH-LOGICAL-c454t-eaa8344a579d15f4ad3e37595774e243cdcb2f82901328d1937ed88dd1df855a3
IEDL.DBID 7X7
ISSN 1078-0998
1536-4844
IngestDate Mon Sep 08 17:30:59 EDT 2025
Mon Sep 08 11:31:09 EDT 2025
Fri Sep 19 20:56:17 EDT 2025
Wed Feb 19 02:43:12 EST 2025
Tue Jul 01 04:19:54 EDT 2025
Thu Apr 24 23:00:15 EDT 2025
Sat Feb 08 08:13:05 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords serum microRNAs
Crohn's disease
blood biomarkers
circulating microRNAs
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c454t-eaa8344a579d15f4ad3e37595774e243cdcb2f82901328d1937ed88dd1df855a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://academic.oup.com/ibdjournal/article-pdf/22/9/2063/23404634/ibd2063.pdf
PMID 27542126
PQID 3169810244
PQPubID 996336
PageCount 7
ParticipantIDs proquest_miscellaneous_1868313995
proquest_miscellaneous_1812888346
proquest_journals_3169810244
pubmed_primary_27542126
crossref_primary_10_1097_MIB_0000000000000883
crossref_citationtrail_10_1097_MIB_0000000000000883
oup_primary_10_1097_MIB_0000000000000883
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-09-01
PublicationDateYYYYMMDD 2016-09-01
PublicationDate_xml – month: 09
  year: 2016
  text: 2016-09-01
  day: 01
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: United States
– name: Baltimore
PublicationTitle Inflammatory bowel diseases
PublicationTitleAlternate Inflamm Bowel Dis
PublicationYear 2016
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Ananthakrishnan (R4-3-20160819) 2015; 12
Solem (R11-3-20160819) 2005; 11
Baltimore (R17-3-20160819) 2008; 9
Duttagupta (R28-3-20160819) 2012; 7
Iskandar (R8-3-20160819) 2012; 159
Polytarchou (R22-3-20160819) 2015; 21
Zahm (R33-3-20160819) 2011; 53
Sincic (R3-3-20160819) 2006; 41
Ordas (R35-3-20160819) 2012; 380
Thia (R2-3-20160819) 2008; 103
Wu (R20-3-20160819) 2008; 135
Chuang (R30-3-20160819) 2014; 20
Dowsett (R23-3-20160819) 2013; 31
van Rooij (R16-3-20160819) 2012; 11
Paraskevi (R26-3-20160819) 2012; 6
Crama-Bohbouth (R7-3-20160819) 1989; 30
Jussila (R6-3-20160819) 2012; 18
Saverymuttu (R10-3-20160819) 1986; 27
Wu (R32-3-20160819) 2011; 17
Koukos (R19-3-20160819) 2013; 145
Zahm (R31-3-20160819) 2014; 8
Schoepfer (R12-3-20160819) 2013; 19
Cho (R15-3-20160819) 2010; 1805
Baumgart (R1-3-20160819) 2007; 369
Hubenthal (R29-3-20160819) 2015; 10
Kosaka (R14-3-20160819) 2010; 101
Li (R24-3-20160819) 2015; 2015
Baumgart (R34-3-20160819) 2012; 380
Lewis (R9-3-20160819) 2011; 140
Mitchell (R13-3-20160819) 2008; 105
Fasseu (R27-3-20160819) 2010; 5
Polytarchou (R36-3-20160819) 2014; 30
Harvey (R5-3-20160819) 1980; 315
Hatziapostolou (R18-3-20160819) 2011; 147
Polytarchou (R21-3-20160819) 2015; 149
Iborra (R25-3-20160819) 2013; 173
References_xml – volume: 369
  start-page: 1627
  year: 2007
  ident: R1-3-20160819
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)60750-8
– volume: 105
  start-page: 10513
  year: 2008
  ident: R13-3-20160819
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0804549105
– volume: 380
  start-page: 1590
  year: 2012
  ident: R34-3-20160819
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)60026-9
– volume: 30
  start-page: 339
  year: 2014
  ident: R36-3-20160819
  publication-title: Curr Opin Gastroenterol
  doi: 10.1097/MOG.0000000000000081
– volume: 12
  start-page: 205
  year: 2015
  ident: R4-3-20160819
  publication-title: Nat Reviews Gastroenterol Hepatol
  doi: 10.1038/nrgastro.2015.34
– volume: 140
  start-page: 1817
  year: 2011
  ident: R9-3-20160819
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2010.11.058
– volume: 27
  start-page: 809
  year: 1986
  ident: R10-3-20160819
  publication-title: Gut
  doi: 10.1136/gut.27.7.809
– volume: 11
  start-page: 707
  year: 2005
  ident: R11-3-20160819
  publication-title: Inflamm Bowel Dis
  doi: 10.1097/01.MIB.0000173271.18319.53
– volume: 30
  start-page: 1236
  year: 1989
  ident: R7-3-20160819
  publication-title: Gut
  doi: 10.1136/gut.30.9.1236
– volume: 147
  start-page: 1233
  year: 2011
  ident: R18-3-20160819
  publication-title: Cell
  doi: 10.1016/j.cell.2011.10.043
– volume: 145
  start-page: 842
  year: 2013
  ident: R19-3-20160819
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2013.07.001
– volume: 21
  start-page: 2533
  year: 2015
  ident: R22-3-20160819
  publication-title: Inflamm Bowel Dis
  doi: 10.1097/MIB.0000000000000547
– volume: 2015
  start-page: 524519
  year: 2015
  ident: R24-3-20160819
  publication-title: Biomed Res Int
– volume: 8
  start-page: 1108
  year: 2014
  ident: R31-3-20160819
  publication-title: J Crohns Colitis
  doi: 10.1016/j.crohns.2014.02.012
– volume: 7
  start-page: e31241
  year: 2012
  ident: R28-3-20160819
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0031241
– volume: 31
  start-page: 2783
  year: 2013
  ident: R23-3-20160819
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.46.1558
– volume: 380
  start-page: 1606
  year: 2012
  ident: R35-3-20160819
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)60150-0
– volume: 6
  start-page: 900
  year: 2012
  ident: R26-3-20160819
  publication-title: J Crohns Colitis
  doi: 10.1016/j.crohns.2012.02.006
– volume: 10
  start-page: e0140155
  year: 2015
  ident: R29-3-20160819
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0140155
– volume: 315
  start-page: 514
  year: 1980
  ident: R5-3-20160819
  publication-title: Lancet
  doi: 10.1016/S0140-6736(80)92767-1
– volume: 53
  start-page: 26
  year: 2011
  ident: R33-3-20160819
  publication-title: J Pediatr Gastroenterol Nutr
  doi: 10.1097/MPG.0b013e31822200cc
– volume: 18
  start-page: 555
  year: 2012
  ident: R6-3-20160819
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.21695
– volume: 135
  start-page: 1624
  year: 2008
  ident: R20-3-20160819
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2008.07.068
– volume: 149
  start-page: 981
  year: 2015
  ident: R21-3-20160819
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2015.05.057
– volume: 17
  start-page: 241
  year: 2011
  ident: R32-3-20160819
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.21450
– volume: 101
  start-page: 2087
  year: 2010
  ident: R14-3-20160819
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2010.01650.x
– volume: 173
  start-page: 250
  year: 2013
  ident: R25-3-20160819
  publication-title: Clin Exp Immunol
  doi: 10.1111/cei.12104
– volume: 1805
  start-page: 209
  year: 2010
  ident: R15-3-20160819
  publication-title: Biochim Biophys Acta
– volume: 11
  start-page: 860
  year: 2012
  ident: R16-3-20160819
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd3864
– volume: 159
  start-page: 313
  year: 2012
  ident: R8-3-20160819
  publication-title: Transl Res
  doi: 10.1016/j.trsl.2012.01.001
– volume: 41
  start-page: 437
  year: 2006
  ident: R3-3-20160819
  publication-title: Scand J Gastroenterol
  doi: 10.1080/00365520500320094
– volume: 19
  start-page: 332
  year: 2013
  ident: R12-3-20160819
  publication-title: Inflamm Bowel Dis
  doi: 10.1097/MIB.0b013e3182810066
– volume: 9
  start-page: 839
  year: 2008
  ident: R17-3-20160819
  publication-title: Nat Immunol
  doi: 10.1038/ni.f.209
– volume: 103
  start-page: 3167
  year: 2008
  ident: R2-3-20160819
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2008.02158.x
– volume: 20
  start-page: 126
  year: 2014
  ident: R30-3-20160819
  publication-title: Inflamm Bowel Dis
  doi: 10.1097/01.MIB.0000436954.70596.9b
– volume: 5
  start-page: e13160
  year: 2010
  ident: R27-3-20160819
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0013160
SSID ssj0020209
Score 2.32722
Snippet Current clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative...
Current clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative...
BackgroundCurrent clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD)....
Background: Current clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD)....
SourceID proquest
pubmed
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2063
SubjectTerms Adult
Biomarkers - blood
C-Reactive Protein - analysis
Case-Control Studies
Circulating MicroRNA - blood
Circulating MicroRNA - genetics
Colon - metabolism
Crohn Disease - blood
Crohn Disease - diagnosis
Crohn Disease - genetics
Crohn's disease
Female
Gene Expression Profiling - methods
Humans
Ileum - metabolism
Male
MicroRNAs
Middle Aged
Nucleic Acid Hybridization - methods
Patients
Title Identification of Circulating MicroRNA Signatures in Crohn's Disease Using the Nanostring nCounter Technology
URI https://www.ncbi.nlm.nih.gov/pubmed/27542126
https://www.proquest.com/docview/3169810244
https://www.proquest.com/docview/1812888346
https://www.proquest.com/docview/1868313995
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFD5sLYy9lO6etSsaDLYX0dm6WH4abdrSDRJGtkLejKxLF2jtNk7__44sOaEbdPObsCyLo9t3bvoAPhipfcHymtaKl5Qz5WnJpKOyqE3mlPCmTxSeTOX5Bf82F_NkcOtSWOWwJ_YbtW1NsJEfskyWCk9Dzr_c3NLAGhW8q4lC4zFsZ4hEAnVDMd8oXJ9jiAdqOMHFX6ohda4sDidfj-PVhcOjFLt3NN1Ld_sLdfanz9ku7CTYSI7iOD-DR655Dk8myTH-Aq5jwq1PFjjSejJeLE3PzdVckkkIu5tNj8iPxWW8yrMji4aMl-2v5mNHTqKXhvTxAwQhIcFNtw2MHlhsQto6Sp9srPAv4eLs9Of4nCYmBWq44CvqtA58GloUpc2E59oyxwpRCgR_LufMWFPnvvepslxZFGXhrFLWZtYrITR7BVtN27g3QLSxtSlRz7K2xhYN4t1cGu81arv4MzYCNgixMuma8cB2cVUN7m4UffWn6EdA11_dxGs2_lH_E47Pf1bdHwaxSuuzqzazaQTv169xZQV3iW5ce9dVAfsobIDLh-pIxbKQHjyC13GCrDuVB3LhLJdvH-7AHjxFECZj3No-bK2Wd-4dAp1VfdDP5gPYPj6dfp9h6WSW_wbRd_cf
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgGXijdbChgJBBerxI_EOVSobKl2abMHaKW9pYkfZSVIymYrxJ_iN3YcJ7sqSIVLc4viONHMeDzjeXwAr3RcuISzkpZKpFRw5WjKY0vjpNSRVdLptlA4m8SjY_FpKqdr8LuvhfFplb1ObBW1qbU_I9_mUZwq3A2FeH_2g3rUKB9d7SE0glgc2F8_0WVrdsZ7yN_XjO1_PBqOaIcqQLWQYkFtUXhsiUImqYmkE4XhlicylWgIWSa4Nrpkro0vcqYMGjiJNUoZExmnpCw4znsDbgofYsT1k0xXDt67kFKCHpVPKUhVX6qXJtvZ-ENoldhfSvFLW-Gl8rq_rNx2t9u_CxudmUp2g1zdgzVb3YdbWReIfwDfQ4Gv6078SO3IcDbXLRZYdUoyn-b3ebJLvsxOQ-vQhswqMpzXX6s3DdkLUSHS5isQNEEJKvnaI4jgbeXL5JHbZHXq_xCOr4XGj2C9qiv7BEihTalT9OuMKXFGjfY1i7VzBXrX-DE-AN4TMdddW3OPrvEt78PrSPr8T9IPgC7fOgttPf4x_i3y5z-HbvVMzDt90OQr6R3Ay-VjXMk-PFNUtj5vcm9rKZxAxFeNiRWPfDnyAB4HAVn-FPNgxhGLN6_-gRdwe3SUHeaH48nBU7jDPJ5xm368BeuL-bl9hkbWonzeSjaBk-teShd_IzEg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+Circulating+MicroRNA+Signatures+in+Crohn%27s+Disease+Using+the+Nanostring+nCounter+Technology&rft.jtitle=Inflammatory+bowel+diseases&rft.au=Oikonomopoulos%2C+Angelos&rft.au=Polytarchou%2C+Christos&rft.au=Joshi%2C+Swapna&rft.au=Hommes%2C+Daniel+W&rft.date=2016-09-01&rft.eissn=1536-4844&rft.volume=22&rft.issue=9&rft.spage=2063&rft_id=info:doi/10.1097%2FMIB.0000000000000883&rft_id=info%3Apmid%2F27542126&rft.externalDocID=27542126
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0998&client=summon